Interleukine 6 as a Predictor of Outcome in Mechanically Ventilated Patients With Covid 19

Serum Interleukine 6 as a Predictor of Outcome in Mechanically Ventilated Patients With Covid 19

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05274503

Enrollment

Registered

2022-03-10

Start date

2021-06-01

Completion date

2022-01-01

Last updated

2022-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mechanical Ventilation Duration

Brief summary

Serum IL-6 levels will be determined by enzyme-linked immunosorbent assay according to the manufacturer's instructions and the normal range is \<10 pg/mL , Patients' medical records will be carefully reviewed and analyzed. Patient data regarding demographics, comorbidities, signs and symptoms, laboratory results and complications will be collected. The occurrence of complications will be confirmed according to the following criteria: acute respiratory distress syndrome (ARDS) defined according to the Berlin definition

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Inclusion criteria

* •Age: more than 20 years. * Gender: both males and females will be included. * Mechanically Ventilated patients. * COVID 19 confirmed diagnosis

Exclusion criteria

* •Immunocompromised patients. * Oxygen saturation more than 95% without ventilation. * Malignancy. * Patients refuse to be enrolled in the study.

Design outcomes

Primary

Measure	Time frame	Description
detection of acute respiratory distress syndrome	2 weeks	hypoxia, incresed plateau pressure

Countries

Egypt

Outcome results